Article Figures & Data
Figures
- Fig 1.
Flow chart of identification of eligible studies.
- Fig 2.
HSROC curve of 18F-FDG-PET for differentiating brain tumors.
- Fig 3.
HSROC curve of 11C-MET PET for differentiating brain tumors.
Tables
- Table 1:
Metaregression analyses and diagnostic performance of 18F-FDG-PET in subgroups of brain tumors
Analysis No. of Studies (pts) I2 of Metaregression (95% CI, P Value) Independent Estimates (95% CI) LR (95% CI) Sensitivity Specificity LR+ LR− Design Retrospective 9 (333) 0.00 (0–100, .86) 0.71 (0.58–0.81) 0.73 (0.57–0.85) 2.63 (1.68–4.13) 0.40 (0.29–0.55) Prospective 15 (524) 0.71 (0.60–0.79) 0.80 (0.66–0.89) 3.45 (1.96–6.07) 0.37 (0.26–0.52) PET or PET/CT PET 17 (511) 0.00 (0–100, .38) 0.74 (0.64–0.81) 0.74 (0.60–0.84) 2.82 (1.74–4.55) 0.36 (0.25–0.51) PET/CT 7 (346) 0.65 (0.50–0.78) 0.84 (0.68–0.92) 3.97 (2.09–7.54) 0.42 (0.29–0.59) PET measurement Qualitative 19 (757) 57.87 (4.96–100, .09) 0.69 (0.60–0.76) 0.79 (0.67–0.87) 3.24 (2.00–5.24) 0.40 (0.30–0.52) Quantitative 4 (85) 0.86 (0.71–0.94) 0.67 (0.43–0.84) 2.59 (1.40–4.81) 0.21 (0.09–0.45) Malignant grade Low 14 (330)a 0.00 (0–100, .46) 0.60 (0.35–0.81) 0.79 (0.64–0.89) 2.87 (1.52–5.41) 0.50 (0.27–0.92) High 17 (473)a 0.74 (0.68–0.80) 0.78 (0.65–0.87) 3.35 (2.09–5.38) 0.33 (0.26–0.42) NS 7 (192) 0.70 (0.50–0.84) 0.70 (0.54–0.82) 2.33 (1.47–3.67) 0.44 (0.26–0.74) Disease status SPBT 3 (127)b 77.72 (51.54–100, .01) 0.43 (0.28–0.59) 0.74 (0.49–0.90) 1.67 (0.59–4.76) 0.77 (0.48–1.24) SRBT 20 (643)b 0.75 (0.67–0.81) 0.79 (0.66–0.88) 3.51 (2.17–5.66) 0.32 (0.25–0.41) Histology Glioma 17 (609)c,d 0.00 (0–100, .47) 0.75 (0.64–0.83) 0.78 (0.64–0.87) 3.36 (2.02–5.59) 0.33 (0.23–0.47) Nonglioma or NS 8 (250)c 0.64 (0.52–0.75) 0.75 (0.63–0.84) 2.58 (1.69–3.94) 0.48 (0.35–0.65) Note:—NS indicates not separable; pts, patients.
↵a Patients with nonneoplastic lesions in 14 studies2,6⇓–8,11,12,15,16,18,19,21,23⇓–25 were used for both low- and high-grade subgroups.
↵b Patients with nonneoplastic lesions in 2 studies8,25 were used for both SPBT and SRBT subgroups.
↵c Five patients with nonneoplastic lesions from Hong et al 201116 were used for both glioma and nonglioma subgroups.
↵d One patient with lymphoma in Pauleit et al 20098 and 2 patients with esthesioblastoma and renal cell metastasis in Kahn et al 199412 were excluded from subgroup analysis.
Analysis No. of Studies (pts) Independent Estimates (95% CI) LR (95% CI) Sensitivity Specificity LR+ LR− Design Prospective 4 (156) 0.91 (0.84–0.95) 0.92 (0.78–0.97) 11.49 (3.87–34.08) 0.10 (0.06–0.18) Retrospective 7 (260) 0.91 (0.81–0.96) 0.84 (0.73–0.90) 5.50 (3.18–9.51) 0.11 (0.05–0.24) PET measurement Qualitative 5 (189) 0.93 (0.87–0.96) 0.85 (0.73–0.92) 6.10 (3.34–11.15) 0.08 (0.04–0.16) Quantitative 6 (227) 0.89 (0.79–0.94) 0.89 (0.74–0.96) 8.38 (3.07–22.88) 0.13 (0.07–0.25) PET or PET/CT PET 7 (232) 0.86 (0.78–0.91) 0.89 (0.72–0.96) 7.96 (2.75–23.00) 0.16 (0.10–0.26) PET/CT 4 (184) 0.95 (0.89–0.97) 0.86 (0.74–0.93) 6.62 (3.48–12.59) 0.06 (0.03–0.13) Malignant grade Low 5 (97)a 0.90 (0.76–0.96) 0.88 (0.77–0.94) 7.44 (3.68–15.02) 0.12 (0.05–0.30) High 7 (132)a 0.98 (0.75–1.00) 0.88 (0.75–0.95) 8.51 (3.78–19.17) 0.02 (0.00–0.34) NS 4 (153) 0.87 (0.79–0.93) 0.87 (0.69–0.96) 6.93 (2.52–19.04) 0.15 (0.08–0.26) Disease status SPBT 2 (85) 0.95 (0.85–0.98) 0.83 (0.65–0.93) 5.49 (2.47–12.21) 0.07 (0.02–0.20) SRBT 8 (238) 0.92 (0.83–0.97) 0.87 (0.75–0.93) 6.81 (3.39–13.69) 0.09 (0.04–0.21) NS 2 (93) 0.88 (0.78–0.94) 0.95 (0.71–0.99) 16.69 (2.47–112.66) 0.13 (0.07–0.24) Histology Glioma 9 (292)b 0.92 (0.85–0.95) 0.87 (0.76–0.93) 7.01 (3.67–13.38) 0.10 (0.05–0.18) Nonglioma and NS 4 (182)b 0.88 (0.79–0.93) 0.83 (0.66–0.92) 5.07 (2.39–10.79) 0.14 (0.08–0.28)
